Compare Avantis International Small Cap Value ETF (AVDV) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis International Small Cap Value ETF vs CVS Health Corp — how do they compare? Avantis International Small Cap Value ETF trades at $109.58, while CVS Health Corp trades at $93.56 (market cap $122.36B). The key difference: CVS Health Corp pays a 2.78% dividend while Avantis International Small Cap Value ETF pays none, and Avantis International Small Cap Value ETF is trading nearer its 52-week high, CVS Health Corp nearer its low. Which is the better fit depends on your goals.
| AVDV | CVS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $110.40 | $110.60 |
52-Week Low | $83.11 | $64.88 |
Market Cap | — | $122.36B |
Enterprise Value | — | $184.71B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVDV trades at $109.63, up 1.34% on the day, with a bullish technical signal from moving averages but caution from oscillators like the RSI. The stock has delivered strong returns recently, including a 35% gain highlighted in June 2026 news, and offers a dividend with a payment scheduled for June 2026. However, key valuation ratios such as P/E and P/B are unavailable, limiting fundamental clarity.
The outlook is mixed: technical strength and positive media coverage on international small-cap value performance support upside, but overbought RSI levels and missing financial metrics pose risks. Investors should weigh the ETF's exposure to developed markets outside the U.S. against potential volatility from commodity sectors, as noted in recent analysis.
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
